Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Genelux Corp

GNLX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.72

▲ +0.00%

Market Cap $123.07M · Vol 107.55K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$123.07M

Micro Cap

Div Yield

N/A

EPS Growth

+4.65%

YoY

RSI (14)

45.83

Momentum

Beta

0.58

vs Market

52W High

$8.54

68.13% below

52W Low

$2.29

18.78% above

Volume

107.55K

Avg 62.53K

P/B

14.24

Price-to-book

ROE

N/A

Return on equity

Free Float

87.01%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Genelux Corp (GNLX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GNLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.74%

-5.88%

-6.85%

-2.51%

YTD

-37.61%

-28.04%

-87.88%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$8.00K
Net Income	$-32,145,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-415,175.00%
Net Profit Margin	-401,812.50%
ROE	N/A
ROA · ROIC	-119.62% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	20,261.21
P/B	14.24
P/FCF	N/A
EPS Growth	+4.65%
Outstanding Shares	45.25M

Technical Indicators

50-Day SMA	$2.86
200-Day SMA	$3.20
RSI (14)	45.83
Beta	0.58
52-Week High	$8.54
52-Week Low	$2.29

Volume Today	107.55K
Avg Daily Volume (30D)	62.53K
Relative Volume	1.72x
Volatility (10D)	40.31
Volatility (30D)	58.62
Free Float	87.01%

Analyst Consensus

BUY

Current Price $2.72

Mean Target $17.50

52W Low$2.29 52W High$8.54

Current

Target

$2.29 $8.54

Current Analyst target

+543.38% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0044BNBY5

ISINUS36870H1032

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -3.94% ARGX.BR argenx SE -4.19% ARGX argenx SE -2.76% INSM Insmed Inc -1.42% 2269.HK WuXi Biologics (Cayman) Inc -4.71%

Company Profile

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.